24 April 2024
Novartis announced today that the National Institute for Health and Care Excellence (NICE) has published its Final Draft Guidance NICE has recommended the combination therapy of dabrafenib (Finlee®) and trametinib (Spexotras®) for the treatment of children with low-grade glioma (LGG)…
Read